-
EP3566718
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3566718
| EP3566718 - A PHARMAZEUTICAL COMBINATION (TREG DEPLETING AGENT, CHECKPOINT INHIBITOR, TLR9 AGONIST) FOR USE IN THE TREATMENT OF CANCER [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 25.03.2022 Database last updated on 29.06.2024 | |
| Former | Request for examination was made Status updated on 08.05.2020 | ||
| Former | The application has been published Status updated on 11.10.2019 | Most recent event Tooltip | 25.03.2022 | Application deemed to be withdrawn | published on 27.04.2022 [2022/17] | Applicant(s) | For all designated states Universitätsmedizin der Johannes Gutenberg-Universität Mainz Langenbeckstraße 1 55131 Mainz / DE | [2019/46] | Inventor(s) | 01 /
ROSIGKEIT, Sebastian Am Römerlager 23 55131 Mainz / DE | 02 /
BOCKAMP, Ernst-Otto Gosenheimer Straße 30 55126 Mainz / DE | 03 /
SCHUPPAN, Detlef Gonsbachblick 12 55122 Mainz / DE | [2019/46] | Representative(s) | Patentanwälte Dr. Keller, Schwertfeger Partnerschaft mbB Westring 17 76829 Landau / DE | [2019/46] | Application number, filing date | 18170999.9 | 07.05.2018 | [2019/46] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3566718 | Date: | 13.11.2019 | Language: | EN | [2019/46] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 06.11.2018 | Classification | IPC: | A61K39/395, A61K39/39, C07K16/28, C12N15/117, A61P35/00, // A61K39/00 | [2019/46] | CPC: |
A61K39/39541 (EP,US);
A61K39/39 (EP,US);
A61K39/3955 (US);
A61K45/06 (US);
A61K9/0019 (US);
A61P35/00 (EP,US);
C07K16/2818 (EP);
C07K16/2866 (EP);
C07K16/2896 (EP);
C12N15/117 (EP,US);
A61K2039/505 (EP);
A61K2039/507 (US);
A61K2039/54 (US);
A61K2039/545 (EP,US);
A61K2039/55561 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/24] |
| Former [2019/46] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | PHARMAZEUTISCHE KOMBINATION (TREG-ABREICHERUNGSMITTEL, CHECKPOINT-INHIBITOR, TLR9-AGONIST) ZUR VERWENDUNG BEI DER KREBS BEHANDLUNG | [2019/46] | English: | A PHARMAZEUTICAL COMBINATION (TREG DEPLETING AGENT, CHECKPOINT INHIBITOR, TLR9 AGONIST) FOR USE IN THE TREATMENT OF CANCER | [2019/46] | French: | COMBINAISON PHARMACEUTIQUE (AGENT D'APPAUVRISSEMENT DE TREG, INHIBITEUR DE POINT DE CONTRÔLE, AGONISTE DU TLR9) POUR LE TRAITEMENT DU CANCER | [2019/46] | Examination procedure | 04.05.2020 | Examination requested [2020/24] | 04.05.2020 | Date on which the examining division has become responsible | 12.05.2020 | Amendment by applicant (claims and/or description) | 01.12.2021 | Application deemed to be withdrawn, date of legal effect [2022/17] | 21.12.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2022/17] | Fees paid | Renewal fee | 27.03.2020 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 31.05.2021 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]WO2016057898 (IDERA PHARMACEUTICALS INC [US]) [I] 1-17 * See claims *; | [I]WO2016109310 (CHECKMATE PHARMACEUTICALS LLC [US]) [I] 1-17 * See claims *; | [A] - H.-J. KIM ET AL, "The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy", CANCER IMMUNOLOGY RESEARCH, US, (201410), vol. 2, no. 10, doi:10.1158/2326-6066.CIR-14-0153, ISSN 2326-6066, pages 926 - 936, XP055517591 [A] 1-17 * the whole document * DOI: http://dx.doi.org/10.1158/2326-6066.CIR-14-0153 | by applicant | WO2016146261 | EP3204040 | WO2015069770 | - SMITH, J. B.; WICKSTROM, E., J. Natl. Cancer Inst., (19980000), vol. 90, pages 1146 - 1154 | - AHMAD, S.; ABU-EID, R.; SHRIMALI, R.; WEBB, M.; VERMA, V.; DOROODCHI, A.; BERRONG, Z.; SAMARA, R.; RODRIGUEZ, P. C.; MKRTICHYAN, M, "Differential PI3K5 Signaling in CD4", Cancer Res, (20170000), vol. 77, pages 1892 - 1904 | - AKIRA, S.; TAKEDA, K.; KAISHO, T., "Toll-like receptors: critical proteins linking innate and acquired immunity", Nat Immunol, (20010000), vol. 2, doi:doi:10.1038/90609, pages 675 - 680, XP002974836 DOI: http://dx.doi.org/10.1038/90609 | - ANTONIA, S. J.; VILLEGAS, A.; DANIEL, D.; VICENTE, D.; MURAKAMI, S.; HUI, R.; YOKOI, T.; CHIAPPORI, A.; LEE, K. H.; DE WIT, M. et, "Durvalumab afterChemoradiotherapy in Stage III Non-Small-Cell Lung Cancer", N Engl J Med, (20170000), vol. 377, pages 1919 - 1929 | - BOWERS, J. S.; MAJCHRZAK, K.; NELSON, M. H.; AKSOY, B. A.; WYATT, M. M.; SMITH, A. S.; BAILEY, S. R.; NEAL, L. R.; HAMMERBACHER, J, "PI3K5Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8", Front Immunol, (20170000), vol. 8, page 1221 | - BRAHMER, J.; RECKAMP, K. L.; BAAS, P.; CRINO, L.; EBERHARDT, W. E.; PODDUBSKAYA, E.; ANTONIA, S.; PLUZANSKI, A.; VOKES, E. E.; HOL, "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer", N Engl J Med, (20150000), vol. 373, doi:doi:10.1056/NEJMoa1504627, pages 123 - 135, XP055391742 DOI: http://dx.doi.org/10.1056/NEJMoa1504627 | - BRAHMER, J. R.; TYKODI, S. S.; CHOW, L. Q.; HWU, W. J.; TOPALIAN, S. L.; HWU, P.; DRAKE, C. G.; CAMACHO, L. H.; KAUH, J.; ODUNSI,, "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", N Engl J Med, (20120000), vol. 366, doi:doi:10.1056/NEJMoa1200694, pages 2455 - 2465, XP002685330 DOI: http://dx.doi.org/10.1056/NEJMoa1200694 | - CARBONE, D. P.; RECK, M.; PAZ-ARES, L.; CREELAN, B.; HORN, L.; STEINS, M.; FELIP, E.; VAN DEN HEUVEL, M. M.; CIULEANU, T. E.; BADI, "First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer", N Engl J Med, (20170000), vol. 376, pages 2415 - 2426 | - CARPENTIER, A.; METELLUS, P.; URSU, R.; ZOHAR, S.; LAFITTE, F.; BARRIE, M.; MENG, Y.; RICHARD, M.; PARIZOT, C.; LAIGLE-DONADEY, F., "Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study", Neuro Oncol, (20100000), vol. 12, doi:doi:10.1093/neuonc/nop047, pages 401 - 408, XP002666157 DOI: http://dx.doi.org/10.1093/neuonc/nop047 | - ETTINGER, D. S.; WOOD, D. E.; AKERLEY, W.; BAZHENOVA, L. A.; BORGHAEI, H.; CAMIDGE, D. R.; CHENEY, R. T.; CHIRIEAC, L. R.; D'AMICO, "NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016", J Natl Compr Canc Netw, (20160000), vol. 14, pages 255 - 264 | - GOSU, V.; BASITH, S.; KWON, O. P.; CHOI, S., "Therapeutic applications of nucleic acids and their analogues in Toll-like receptor signaling", Molecules, (20120000), vol. 17, doi:doi:10.3390/molecules171113503, pages 13503 - 13529, XP055108462 DOI: http://dx.doi.org/10.3390/molecules171113503 | - GOVINDAN, R.; SZCZESNA, A.; AHN, M. J.; SCHNEIDER, C. P.; GONZALEZ MELLA, P. F.; BARLESI, F.; HAN, B.; GANEA, D. E.; VON PAWEL, J., "Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer", J Clin Oncol, (20170000), vol. 35, pages 3449 - 3457 | - GUERRA, C.; MIJIMOLLE, N.; DHAWAHIR, A.; DUBUS, P.; BARRADAS, M.; SERRANO, M.; CAMPUZANO, V.; BARBACID, M., "Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context", Cancer Cell, (20030000), vol. 4, pages 111 - 120 | - HAMEYER, D.; LOONSTRA, A.; ESHKIND, L.; SCHMITT, S.; ANTUNES, C.; GROEN, A.; BINDELS, E.; JONKERS, J.; KRIMPENFORT, P.; MEUWISSEN,, "Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues", Physiol Genomics, (20070000), vol. 31, doi:doi:10.1152/PHYSIOLGENOMICS.00019.2007, pages 32 - 41, XP002525189 DOI: http://dx.doi.org/10.1152/PHYSIOLGENOMICS.00019.2007 | - HELLMANN, M. D.; RIZVI, N. A.; GOLDMAN, J. W.; GETTINGER, S. N.; BORGHAEI, H.; BRAHMER, J. R.; READY, N. E.; GERBER, D. E.; CHOW,, "Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study", Lancet Oncol, (20170000), vol. 18, doi:doi:10.1016/S1470-2045(16)30624-6, pages 31 - 41, XP029868855 DOI: http://dx.doi.org/10.1016/S1470-2045(16)30624-6 | - HEMMI, H.; TAKEUCHI, O.; KAWAI, T.; KAISHO, T.; SATO, S.; SANJO, H.; MATSUMOTO, M.; HOSHINO, K.; WAGNER, H.; TAKEDA, K., "A Toll-like receptor recognizes bacterial DNA", Nature, (20000000), vol. 408, pages 740 - 745 | - HERBST, R. S.; SORIA, J. C.; KOWANETZ, M.; FINE, G. D.; HAMID, O.; GORDON, M. S.; SOSMAN, J. A.; MCDERMOTT, D. F.; POWDERLY, J. D., "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients", Nature, (20140000), vol. 515, doi:doi:10.1038/nature14011, pages 563 - 567, XP055262130 DOI: http://dx.doi.org/10.1038/nature14011 | - HORNUNG, V.; ROTHENFUSSER, S.; BRITSCH, S.; KRUG, A.; JAHRSDORFER, B.; GIESE, T.; ENDRES, S.; HARTMANN, G., "Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides", J Immunol, (20020000), vol. 168, pages 4531 - 4537, XP002438973 | - JONKERS, J.; MEUWISSEN, R.; VAN DER GULDEN, H.; PETERSE, H.; VAN DER VALK, M.; BERNS, A., "Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer", Nat Genet, (20010000), vol. 29, pages 418 - 425 | - KARBACH, J.; NEUMANN, A.; ATMACA, A.; WAHLE, C.; BRAND, K.; BOEHMER, L.; KNUTH, A.; BENDER, A.; RITTER, G.; OLD, L. J., "Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients", Clin Cancer Res, (20110000), vol. 17, pages 861 - 870 | - LI, K.; QU, S.; CHEN, X.; WU, Q.; SHI, M., "Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways", Int J Mol Sci, (20170000), page 18 | - MEDZHITOV, R., "Toll-like receptors and innate immunity", Nat Rev Immunol, (20010000), vol. 1, pages 135 - 145 | - MIKULANDRA, M.; PAVELIC, J.; GLAVAN, T. M., "Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy", Curr Med Chem, (20170000), vol. 24, pages 2011 - 2032 | - NOVELLO, S.; BARLESI, F.; CALIFANO, R.; CUFER, T.; EKMAN, S.; LEVRA, M. G.; KERR, K.; POPAT, S.; RECK, M.; SENAN, S. et al., "Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, (20160000), vol. 27, pages v1 - v27 | - ONIZUKA, S.; TAWARA, I.; SHIMIZU, J.; SAKAGUCHI, S.; FUJITA, T.; NAKAYAMA, E., "Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody", Cancer Res, (19990000), vol. 59, pages 3128 - 3133, XP002255931 | - RAWLINS, E. L.; OKUBO, T.; XUE, Y.; BRASS, D. M.; AUTEN, R. L.; HASEGAWA, H.; WANG, F.; HOGAN, B. L., "The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium", Cell Stem Cell, (20090000), vol. 4, doi:doi:10.1016/j.stem.2009.04.002, pages 525 - 534, XP055090016 DOI: http://dx.doi.org/10.1016/j.stem.2009.04.002 | - SCHEIERMANN, J.; KLINMAN, D. M., "Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer", Vaccine, (20140000), vol. 32, doi:doi:10.1016/j.vaccine.2014.06.065, pages 6377 - 6389, XP029092481 DOI: http://dx.doi.org/10.1016/j.vaccine.2014.06.065 | - SCHNEBERGER, D.; CALDWELL, S.; KANTHAN, R.; SINGH, B., "Expression of Toll-like receptor 9 in mouse and human lungs", J Anat, (20130000), vol. 222, pages 495 - 503 | - SHI, M.; CHEN, X.; YE, K.; YAO, Y.; LI, Y, "Application potential of toll-like receptors in cancer immunotherapy: Systematic review", Medicine (Baltimore, (20160000), vol. 95, page e3951 | - SMITH, J. B.; WICKSTROM, E., "Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model", J Natl Cancer Inst, (19980000), vol. 90, pages 1146 - 1154 | - TANAKA, A.; SAKAGUCHI, S., "Regulatory T cells in cancer immunotherapy", Cell Res, (20170000), vol. 27, pages 109 - 118 | - TOPALIAN, S. L.; HODI, F. S.; BRAHMER, J. R.; GETTINGER, S. N.; SMITH, D. C.; MCDERMOTT, D. F.; POWDERLY, J. D.; CARVAJAL, R. D.;, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, (20120000), vol. 366, doi:doi:10.1056/NEJMoa1200690, pages 2443 - 2454, XP055098235 DOI: http://dx.doi.org/10.1056/NEJMoa1200690 | - URSU, R.; CARPENTIER, A.; METELLUS, P.; LUBRANO, V.; LAIGLE-DONADEY, F.; CAPELLE, L.; GUYOTAT, J.; LANGLOIS, O.; BAUCHET, L.; DESS, "Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study", Eur J Cancer, (20170000), vol. 73, pages 30 - 37 | - YANG, Y.; HUANG, C. T.; HUANG, X.; PARDOLL, D. M., "Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance", Nat Immunol, (20040000), vol. 5, pages 508 - 515 |